Summary
Thermo Fisher Scientific Inc. (TMO) announced an underwritten public offering of $1.3 billion in senior notes, comprising $500 million of 1.850% Senior Notes due 2018 and $800 million of 3.150% Senior Notes due 2023. The primary purpose of this debt issuance is to finance the anticipated cash consideration for its acquisition of One Lambda, Inc., estimated at approximately $925 million, along with associated acquisition costs. This strategic move indicates Thermo Fisher's commitment to expanding its business through targeted acquisitions, leveraging debt financing to fund significant growth opportunities.
Key Highlights
- 1Thermo Fisher Scientific Inc. successfully priced a public offering of $1.3 billion in senior notes.
- 2The offering consists of $500 million in 1.850% Senior Notes due 2018 and $800 million in 3.150% Senior Notes due 2023.
- 3Net proceeds are expected to be approximately $1.285 billion after deducting underwriting discounts and estimated expenses.
- 4The primary use of proceeds is to fund the cash consideration for the acquisition of One Lambda, Inc.
- 5The One Lambda acquisition is estimated to cost approximately $925 million in cash.
- 6The company has alternative financing plans, including revolving credit facilities and commercial paper, to cover any shortfall.
- 7The issuance is being conducted under a registration statement on Form S-3 previously filed with the SEC.
Frequently Asked Questions
The main purpose of this debt issuance is to raise capital to fund the cash consideration for Thermo Fisher Scientific's acquisition of One Lambda, Inc., and to cover associated acquisition costs. This demonstrates the company's strategy to finance significant growth through strategic acquisitions.
Thermo Fisher Scientific is issuing a total of $1.3 billion in senior notes. This includes $500 million of 1.850% Senior Notes due 2018 and $800 million of 3.150% Senior Notes due 2023.
The 8-K filing states that One Lambda, Inc. is a California corporation. While the filing doesn't detail the strategic rationale for the acquisition, it indicates its importance by being the primary use of the proceeds from this significant debt offering. Investors would typically look for more information on One Lambda's business in subsequent filings or press releases to understand the strategic fit and expected synergies.
If the company is unable to issue the Notes in the anticipated amounts, Thermo Fisher Scientific intends to finance any shortfall through a combination of borrowings under its existing revolving credit facilities and/or the issuance of commercial paper. This indicates flexibility in their financing strategy.